What is McKesson's biggest risk?

The main watch-item is a pending False Claims Act case tied to oncology drug overfill billing, with discovery and summary judgment briefing expected around July 2026 and a ruling anticipated by December 2026. A second item to track is the planned separation of its Medical-Surgical Solutions unit into an independent public company, targeted for completion by December 2027, which could change the parent company's revenue mix.

Is McKesson in financial trouble?

No signs of financial trouble appear in the evidence. FY2025 revenue was $359.05 billion as of March 31, 2025, and FY2026 revenue grew 12% year over year with adjusted EPS growth of 18% as of March 31, 2026. Market capitalization stood at $90.6 billion as of May 12, 2026, and free cash flow reached $5.4 billion for the fiscal year.

Who are McKesson's biggest competitors?

McKesson competes mainly with Cardinal Health and Cencora, the other two members of the Big Three that control over 90% of U.S. drug distribution. McKesson holds near-equal share with Cencora and pulled ahead of Cardinal Health after winning the OptumRx distribution contract in mid-2025, a deal worth more than $35 billion in trailing revenue.

Is McKesson at risk from AI?

Not based on current evidence. AI can automate parts of claims processing and dispensing workflows, but it cannot move controlled substances or replace the DEA-licensed warehouses and truck fleets that McKesson relies on. Our July 2026 assessment of 185 companies in its category found McKesson's business to be highly physical and regulatory, reinforced by its position within the three-company oligopoly, alongside Cardinal Health and Cencora, that controls over 90% of U.S. drug distribution.

Could a big tech company like Amazon take over McKesson's business?

That looks distant right now. Amazon Pharmacy has not built a rival wholesale distribution network as of 2026, and UnitedHealth's Optum actually renewed its McKesson contract in 2025 rather than building its own distribution capability. Our July 2026 assessment of 185 companies in its category found McKesson's regulatory licensing requirements and decades of logistics scale create a high barrier for any new entrant, including a tech giant, to clear.

What does McKesson's overall durability profile look like?

McKesson is rated hard to displace, the strongest standing tier in this evidence base. Its protection comes from regulatory licensing requirements, decades of logistics scale, and entrenched contracts with pharmacies and health systems, the same forces that keep the distribution business concentrated among just three national players controlling over 90% of the market. Our July 2026 assessment found these advantages to be deeply entrenched and hard to erode.

Pharma and healthcare groups · United States

McKesson

mckesson.com ↗

Drug wholesaler moving roughly a third of North America's prescription medicines.

Hard to displace

Assessed 30 July 2026 · Evidence as of 30 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 30 July 2026 · Checkable from early August 2026 · Every call on the record Checkpoint: Q1 FY2027 earnings release

The call

McKesson moves the physical drug supply that no algorithm can replace, while watching whether its biggest customers ever decide to build that machinery themselves.

McKesson buys drugs from manufacturers and sells them to hospitals, pharmacies, and health systems across North America. It is hard to replace because it owns the trucks and warehouses, holds special government licenses to handle controlled drugs, and has contracts locked in for years with the biggest suppliers and buyers. The main risk is not that Amazon or AI will steal the business, but that cheaper drugs and new weight-loss medicines shift what doctors prescribe, squeezing McKesson's profit per pill.

Why

AI pressure: None apparent. AI can't drive a truck, hold a DEA license, or replace warehouse networks; McKesson uses AI to trim its own costs. Could AI do the core job? Unlikely.

Bigger players: UnitedHealth/Optum vertical integration. Optum just handed McKesson its ~$35B/yr contract, but a future in-house Optum distribution arm could pull that volume back. Could a giant copy it? No, they are blocked.

What protects it. DEA-licensed warehouses, drug pedigree systems, and multi-year contracts with manufacturers, payers, and hospitals that took decades to build.

What would change this call

Amazon announces full-line hospital/health-system wholesale distribution with named contracted volume. Would show a new-model rival entering McKesson's core distribution business.
Optum announces it is bringing pharmacy distribution in-house and pulling the OptumRx contract from McKesson. Would show vertical integration eroding McKesson's largest new contract win.
Cencora or Cardinal Health publicly wins a major distribution contract previously held by McKesson. Would show share flowing back to oligopoly peers rather than toward McKesson.

Key numbers

FY2025 revenue about $359 billion (2025-03-31)
Apollo paid $1.25B for 13% of Medical-Surgical unit, ~$13B value (2026-04-20)
Q1 CY2026 revenue $96.3B, missed estimates by 5.3% (2026-03-31)

Named risks

IRA-driven branded drug price declines and GLP-1 volume swings pressuring margins and revenue. Severity: high
Execution risk in Medical-Surgical Solutions IPO and separation from McKesson. Severity: medium
Optum vertically integrates and pulls the ~$35B OptumRx contract in house. Severity: medium
Residual state-level opioid litigation exposure beyond the settled $7.4B national deal. Severity: low
Amazon or another entrant scales into full-line hospital/health-system distribution. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Cardinal Health	losing to	Lost ~$35B/yr OptumRx distribution contract to McKesson in mid-2025
Cencora	contesting	Together with Cardinal, controls over 90% of US drug distribution alongside McKesson as of 2026-05-13
UnitedHealth/Optum	contesting	Vertical integration risk flagged if Optum pulls the ~$35B OptumRx contract in house
Amazon Pharmacy	gaining on	Amazon Pharmacy remains DTC-only as of mid-2026, no full-line hospital wholesale distribution launched

Questions people ask

What is McKesson's biggest risk?: The main watch-item is a pending False Claims Act case tied to oncology drug overfill billing, with discovery and summary judgment briefing expected around July 2026 and a ruling anticipated by December 2026. A second item to track is the planned separation of its Medical-Surgical Solutions unit into an independent public company, targeted for completion by December 2027, which could change the parent company's revenue mix.
Is McKesson in financial trouble?: No signs of financial trouble appear in the evidence. FY2025 revenue was $359.05 billion as of March 31, 2025, and FY2026 revenue grew 12% year over year with adjusted EPS growth of 18% as of March 31, 2026. Market capitalization stood at $90.6 billion as of May 12, 2026, and free cash flow reached $5.4 billion for the fiscal year.
Who are McKesson's biggest competitors?: McKesson competes mainly with Cardinal Health and Cencora, the other two members of the Big Three that control over 90% of U.S. drug distribution. McKesson holds near-equal share with Cencora and pulled ahead of Cardinal Health after winning the OptumRx distribution contract in mid-2025, a deal worth more than $35 billion in trailing revenue.
Is McKesson at risk from AI?: Not based on current evidence. AI can automate parts of claims processing and dispensing workflows, but it cannot move controlled substances or replace the DEA-licensed warehouses and truck fleets that McKesson relies on. Our July 2026 assessment of 185 companies in its category found McKesson's business to be highly physical and regulatory, reinforced by its position within the three-company oligopoly, alongside Cardinal Health and Cencora, that controls over 90% of U.S. drug distribution.
Could a big tech company like Amazon take over McKesson's business?: That looks distant right now. Amazon Pharmacy has not built a rival wholesale distribution network as of 2026, and UnitedHealth's Optum actually renewed its McKesson contract in 2025 rather than building its own distribution capability. Our July 2026 assessment of 185 companies in its category found McKesson's regulatory licensing requirements and decades of logistics scale create a high barrier for any new entrant, including a tech giant, to clear.
What does McKesson's overall durability profile look like?: McKesson is rated hard to displace, the strongest standing tier in this evidence base. Its protection comes from regulatory licensing requirements, decades of logistics scale, and entrenched contracts with pharmacies and health systems, the same forces that keep the distribution business concentrated among just three national players controlling over 90% of the market. Our July 2026 assessment found these advantages to be deeply entrenched and hard to erode.

Timeline

2026-07-13McKesson releases FY26 impact report citing ~1/3 North American drug distribution share
2026-06-10Reimagine Care (McKesson Ventures) expands AI oncology model with Moffitt Cancer Center
2026-06-01Apollo Funds minority investment in Medical-Surgical Solutions deal closes
2026-05-01Brian Tyler elected Chair; Dominic Caruso named Lead Independent Director
2026-04-30McKesson secures $2.0B financing ($1.0B term loan, $1.0B revolver) for MMS separation
2026-04-20McKesson signs Apollo Funds agreement for MMS minority stake, ~$13B enterprise value
2026-03-31FY2026 closes with $5.4B free cash flow, $5.1B returned to shareholders
2026-01-30McKesson completes exit of Norway retail/distribution business, ending European presence
2025-06-30McKesson wins OptumRx distribution contract away from Cardinal Health, worth $35B+ over 12 months
2022-12-31McKesson finalizes $7.4 billion national opioid settlement share

Head to head

Cardinal Health vs McKesson Cencora vs McKesson

Revision history

30 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Vertex Pharmaceuticals Tenet Healthcare Intuitive Surgical

More in Pharma and healthcare groups →

Sources